Torii Pharmaceutical Co (TSE:4551) EV-to-EBIT : 8.45 (As of May. 31, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Torii Pharmaceutical Co's Enterprise Value is 円60,511 Mil. Torii Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was 円7,158 Mil. Therefore, Torii Pharmaceutical Co's EV-to-EBIT for today is 8.45.

The historical rank and industry rank for Torii Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:

TSE:4551' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.49 Med: 6.71 Max: 17.99
Current: 8.45

During the past 13 years, the highest EV-to-EBIT of Torii Pharmaceutical Co was 17.99. The lowest was -27.49. And the median was 6.71.

TSE:4551's EV-to-EBIT is ranked better than
79.19% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.705 vs TSE:4551: 8.45

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Torii Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2024 was 円74,132 Mil. Torii Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was 円7,158 Mil. Torii Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 9.66%.

Torii Pharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Torii Pharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Torii Pharmaceutical Co EV-to-EBIT Chart

Torii Pharmaceutical Co Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

0.25

4.88

3.31

6.07

10.04

Torii Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															10.41	12.42	12.98	10.04	10.36

Competitive Comparison of Torii Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Torii Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Torii Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torii Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Torii Pharmaceutical Co's EV-to-EBIT falls into.

Torii Pharmaceutical Co EV-to-EBIT Calculation

Torii Pharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	60511.092	/	7158
	=	8.45

Torii Pharmaceutical Co's current Enterprise Value is 円60,511 Mil.
Torii Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円7,158 Mil.

Torii Pharmaceutical Co (TSE:4551) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Torii Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	7158	/	74131.742
	=	9.66 %

Torii Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2024 was 円74,132 Mil.
Torii Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円7,158 Mil.

Torii Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Torii Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Torii Pharmaceutical Co (TSE:4551) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439

Website

http://www.torii.co.jp

Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines